A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia (NCT02064010) | Clinical Trial Compass
WithdrawnPhase 2
A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Stopped: Funding terminated; company closed
United States0Started 2014-02
Plain-language summary
This Phase 2 study was designed to evaluate the efficacy and safety of SNC-102 in subjects with drug-induced Tardive Dyskinesia (TD). To ensure an adequate evaluation of SNC-102, a randomized, double-blind, parallel-group, placebo-controlled trial was designed. Two dosing levels of SNC-102 are employed to evaluate the proposed dosing range. A target enrollment of 90 subjects with drug-induced TD will provide sufficient data to assess the efficacy and safety profiles of SNC-102 in the target population.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females 18-75 years of age.
✓. Diagnosis, at least 3 months prior to the Screening Visit, of drug-induced TD
✓. AIMS ≥3 (moderate or worse) for ≥1 body area, or AIMS = 2 (mild) for ≥2 body areas; and
✓. \>3 months exposure to antipsychotic drug or metoclopramide; and
✓. Other causes of dyskinesia have been ruled out.
✓. AIMS score is confirmed at the Screening Visit by the Principal Investigator and the Trial Reading Center, and at the Baseline Visit at least 1 week later by the Principal Investigator.
✓. If using antipsychotic medication or metoclopramide, dose has been stable for at least 60 days prior to the Baseline Visit and is expected to remain stable through the course of the trial.
✓. If using opioid medication, dose has been stable for at least 14 days prior to the Baseline Visit and is expected to remain stable through the course of the trial.
Exclusion criteria
✕. Unstable psychiatric status, as indicated by any change in psychotropic medication (unless approved by the Sponsor), or by hospitalization, within 60 days prior to the Screening Visit.
✕. Active drug or alcohol dependence or abuse.
✕. Current use of cocaine, amphetamine, phencyclidine (PCP), or ketamine, documented either by history or by urinary drug screening at Screening and Baseline Visits. Drugs used to treat attention deficit-hyperactivity disorder are allowed if stable for at least 14 days prior to the Baseline Visit and are expected to remain stable through the course of the trial.
What they're measuring
1
Efficacy as measured by changes from baseline in summary scores on the Abnormal Involuntary Movement Scale (AIMS)
✕. Risk of significant medication non-adherence, based on the judgment of the Principal Investigator.
✕. Neurologic or psychiatric disorder that could interfere with the attribution of observed involuntary movements to TD, such as a primary movement disorder unrelated to medication.
✕. History of neuroleptic malignant syndrome.
✕. Significant risk, in the judgment of the Principal Investigator, of suicidal or violent behavior.
✕. Receipt of new medication for the treatment of TD within 4 weeks prior to the Baseline Visit or anticipated while participating in the trial.